メインコンテンツに移動

Keeping one step ahead of the innovators

Kilkenny Capital Management has been making healthy returns out of the biotechnology sector for more than a decade. Jay Blanche met up with the top brass while they were in London, to find out how they do it

There can't be many people in the hedge fund industry that could comfortably say they know what makes a good investment in the realm of biotechnology.

The producers in the industry are necessarily cagey about what they are working on, and most, if not all, hedge fund managers probably wouldn't fully understand it. Most investors, that is.

Michael Walsh, founder of Kilkenny Capital Management, is

コンテンツを印刷またはコピーできるのは、有料の購読契約を結んでいるユーザー、または法人購読契約の一員であるユーザーのみです。

これらのオプションやその他の購読特典を利用するには、info@risk.net にお問い合わせいただくか、こちらの購読オプションをご覧ください: http://subscriptions.risk.net/subscribe

現在、このコンテンツをコピーすることはできません。詳しくはinfo@risk.netまでお問い合わせください。

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Risk.net? View our subscription options

Most read articles loading...

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

ログイン
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here